•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
The DJS Law Group has reminded investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company,” NASDAQ: CORT) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S. Securities and Exchange Commission.
According to the Complaint, the Company made false and misleading statements to the market during the class period. The filing alleges that, despite an FDA warning to Corcept “on several occasions” that the clinical data on its product candidate relacorilant was insufficient, Corcept told investors that the product was “approaching approval” based on the “powerful evidence” it said it had gathered in trials.
The Complaint further alleges that Corcept’s public statements were false and materially misleading throughout the class period.
Shareholders who purchased shares of CORT during the class period are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to participate in any recovery.
David J. Schwartz, DJS Law Group, 274 White Plains Road, Suite 1, Eastchester, NY 10709. Phone: 914-206-9742. Email: [redacted].
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
